Atlas Trials

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

Clinical trial NCT02565914 · COMPLETED

Trial details

NCT number
NCT02565914
Sponsor
Vertex Pharmaceuticals Incorporated
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Cystic Fibrosis
Start date
2015-08-01
Primary completion
2019-05-01
Enrollment
1131

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.